Ferrer-Font L, Arias-Ramos N, Lope-Piedrafita S, Julià-Sapé M, Pumarola M, Arús C, Candiota AP. Metronomic treatment in immunocompetent preclinical GL261 glioblastoma: effects of cyclophosphamide and temozolomide. NMR Biomed. 2017 Sep;30(9). doi: 10.1002/nbm.3748. Epub 2017 Jun 1. PMID: 28570014.
Jiménez-Xarrié E, Davila M, Candiota AP, Delgado-Mederos R, Ortega-Martorell S, Julià-Sapé M, Arús C, Martí-Fàbregas J. Brain metabolic pattern analysis using a magnetic resonance spectra classification software in experimental stroke. BMC Neurosci. 2017 Jan 13;18(1):13. doi: 10.1186/s12868-016-0328-x. PMID: 28086802; PMCID: PMC5237280.
Ferrer-Font L, Villamañan L, Arias-Ramos N, Vilardell J, Plana M, Ruzzene M, Pinna LA, Itarte E, Arús C, Candiota AP. Targeting Protein Kinase CK2: Evaluating CX-4945 Potential for GL261 Glioblastoma Therapy in Immunocompetent Mice. Pharmaceuticals (Basel). 2017 Feb 12;10(1):24. doi: 10.3390/ph10010024. PMID: 28208677; PMCID: PMC5374428.
Arias-Ramos N, Ferrer-Font L, Lope-Piedrafita S, Mocioiu V, Julià-Sapé M, Pumarola M, Arús C, Candiota AP. Metabolomics of Therapy Response in Preclinical Glioblastoma: A Multi-Slice MRSI-Based Volumetric Analysis for Noninvasive Assessment of Temozolomide Treatment. Metabolites. 2017 May 18;7(2):20. doi: 10.3390/metabo7020020. PMID: 28524099; PMCID: PMC5487991.